---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-24-000042"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:54:35.662911+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics doses first patient in Phase 3 sarcoma trial; cash $6.3M into Q1 2025

## Summary
- First patient dosed in Phase 3 INVINCIBLE-3 study of INT230-6 vs SOC in soft tissue sarcoma; plans 333 patients.
- Collaboration with SAKK for Phase 2 INVINCIBLE-4 study in early-stage triple-negative breast cancer; start Q3 2024.
- Net loss $5.0M in Q2 2024 vs $3.7M in Q2 2023; R&D expenses $3.6M (up from $0.9M).
- Cash, cash equivalents and marketable debt securities $6.3M as of June 30, 2024.
- Appointed Thomas Dubin, J.D., MPH to board of directors.

## SEC filing metadata
- accession: 0001567264-24-000042
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000042/0001567264-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000042/intensity-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-24-000042
- JSON: https://secwatch.observer/filing/0001567264-24-000042.json
- Plain text: https://secwatch.observer/filing/0001567264-24-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.